According to the results of the hematoxylin and eosin (H/E) and immunohistochemical staining of the xenograft model, the combination group inhibited the tumor growth and expressions of RAB3C and dystrophin (Fig. 4G), which suggests that CB2 agonists may provide an additional treatment option for patients with colon cancer, and that they have a synergistic effect in combination with regorafenib. Here, DMD is linked to neoplasm.